Lucentis diabeediga makulaarse ödeemi ülevaadetes

Immunogenicity. As with all therapeutic proteins, there is the potential for an immune response in patients treated with Lucentis. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to Lucentis in immunoassays and are highly dependent on the sensitivity and specificity of the assays.

Mis teravilja diabeediga süüa

Lucentis is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Lucentis is the brand name for the drug, which is called ranibizumab.

You may look:
-> 2. tüüpi diabeedi ravi ja toitumine
About Diabetic Macular Edema. Diabetic macular edema is a build-up of blood and fluid in the macula and can occur at any stage of diabetic retinopathy. Because the macula is the part of the eye needed for sharp, straight-ahead vision, damage to this area can cause dramatic vision problems. DME is the most common cause of diabetes-related vision.
-> Madal veresuhkru hägusus silmades
Lucentis (Ranibizumab injection) Lucentis® (ranibizumab injection) is a prescription medicine for the treatment of people with wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
-> Miks oksendamine diabeetilise gangreeniga
LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL LUCENTIS solution) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to 3 months. Patients may be retreated if needed [(see Clinical Studies 14.5)].
-> Diabeedi testid
Monitor intraocular pressure prior to and following intravitreal injection with LUCENTIS and manage appropriately. Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors.
-> Vaskulaarsed anumad pärast ballooni angioplastikat võivad olla diabeetilise jala ajal ummistunud
LUCENTIS ® (ranibizumab injection) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A).




Lucentis diabeediga makulaarse ödeemi ülevaadetes:

Rating: 261 / 2
Overall: 5 Rates